Phenotyping HF Using EF: What’s the Underlying Pathophysiology

Description

Leaning Objectives
Upon completion of this activity, you should be able to: 

Evaluate the epidemiology, risk factors, comorbidities, and community aspects associated with Heart Failure (HF) to determine best practices for care.
Distinguish pathophysiologic characteristics when evaluating and diagnosing HF, including current classifications, genotypes, and phenotypes, to best analyze HF risk stratification, prevention, and management strategies.

Faculty

Selma F. Mohammed, MD, PhD

Creighton University

Disclosure

Nothing to disclose.

Justin M. Vader, MD, FACC

Washington University

Disclosure

Nothing to disclose.

Target Audience  
The primary target audience for this education are members of the HF Care Team, including physicians, advanced practice providers (APPs), PharmDs, and other HCPs.

Important Dates 
Date of Release: March 5, 2026
Term of Approval/Date of Expiration: March 3, 2028

Acknowledgement
This activity is supported by an unrestricted educational grant from Bayer AG.

Summary

Availability:

On-Demand

Access expires on Mar 03, 2028

Cost:

FREE

Credit Offered:

No Credit Offered